Palvella Therapeutics, Inc.

PVLA

NASDAQ

Healthcare

Biotechnology

Wayne, PA, US14 employeespalvellatx.com

$122.89

+2.51(2.08%)

Mkt Cap $1.5B

$19.87

$148.34

52-Week Range

At a Glance

AI-generated

Operating and net losses deepened to -$38.6M and -$41.7M respectively in FY2025 from -$14.1M and -$17.4M prior year, driven by clinical investments and public company scaling costs amid no revenue generation.

8-K

Palvella Therapeutics filed an 8-K on March 31, 2026 disclosing 2025 full-year financial results and key corporate and pipeline updates for investors.

$1.5B

Market Cap

—

Revenue

-$35M

Net Income

Employees14

Fundamentals

How The Business Makes Money

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

Industry Biotechnology

Activity

What Changed Recently

Financial Results

Mar 30, 2026

, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act

Material Agreement

Feb 25, 2026

Entry into a Material Definitive Agreement On February 25, 2026, Palvella Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underw

Financial Results

Feb 23, 2026

is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”)

Regulation FD

Feb 23, 2026

, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth

Other Event

Feb 23, 2026

Other Events. On February 24, 2026, Palvella Therapeutics, Inc. (the “ Company ”) issued a press release announcing positive topline results from the Company’s

Peer Companies

Company	Price	Change	Market Cap	P/E
TYRATyra Biosciences, Inc.	$39.38	+2.89%	$2.1B	-18.1
NBTXNanobiotix S.A.	$31.09	-8.76%	$1.5B	-23.8
SVRASavara Inc.	$5.57	-0.27%	$1.1B	-9.5
EYPTEyePoint Pharmaceuticals,...	$13.41	+3.00%	$1.1B	-4.6
GHRSGH Research PLC	$14.47	-1.66%	$898M	-17.0
ABUSArbutus Biopharma Corpora...	$4.50	-0.55%	$879M	-25.3
SPRYARS Pharmaceuticals, Inc.	$8.29	+2.28%	$824M	-4.4
KURAKura Oncology, Inc.	$8.62	+3.36%	$761M	-2.6

Analyst View

Company Profile

CIK0001583648

ISINUS6979471090

CUSIP697947109

Phone484 253 1461

Address125 Strafford Avenue, Wayne, PA, 19087, US

SEC EDGAR